With this announcement, for reasons of transparency, AOK Bayern publishes all contracts concluded within the framework of the open house procedures for drug discount contracts pursuant to § 130a(8) SGB V and § 130a(8)(c) SGB V in the period from 15.06.2024 to 15.07.2024. AOK Bayern intends to conclude non-exclusive rebate agreements with all interested pharmaceutical companies on the active substances mentioned in the respective procedure pursuant to § 130a(8) SGB V or § 130a(8)(c) SGB V. AOK Bayern offers all interested pharmaceutical companies that meet the eligibility requirements listed below the conclusion of identical and non-individually negotiable discount agreements. A contract can be concluded at any time during the term. Contracts may be terminated with a notice period of one month to the end of the month. Upon entry into force of a rebate agreement for medicinal products with the active substance subject to the contract concluded by means of a nationwide or country-specific rebate agreement concluded in an open procedure, the open-house agreements automatically cease to apply for the corresponding term. A contract is concluded with all interested pharmaceutical companies that prove their suitability by means of a completed and signed self-declaration of reliability. Details can be found in the contract notice for the respective open house procedure in the Official Journal of the European Union. Contracts concluded between 15.06.2024 and 15.07.2024: 1. Abatacept: axicorp Pharma B.V., The Hague, The Netherlands; Abacus Medicine A/S, Copenhagen, Denmark 2. Adalimumab: 1 0 1 Carefarm GmbH, Leverkusen; INOPHA GmbH, Ludwigsfelde; Aaragon Pharma s.r.o., Hostivice, Czech Republic; Orifarm GmbH, Leverkusen 3. Ambrisentan: Cipla Europe NV, Antwerp, Belgium; GlaxoSmithKline GmbH & Co. KG, Munich 4. Bimatoprost: Micro Labs GmbH, Frankfurt am Main; Aliud Pharma GmbH, Laichingen; 1 A Pharma GmbH, Holzkirchen; AbbVie Deutschland GmbH & Co. KG, Wiesbaden 5. dabigatran etexilate: Glenmark Arzneimittel GmbH, Gröbenzell 6. Erythropoietin alfa: EMRA-MED Arzneimittel GmbH, Trittau 7. Fondaparinux: Viatris Healthcare GmbH, Bad Homburg 8. Infliximab: INOPHA GmbH, Ludwigsfelde 9. Interferon beta-1a Rebif: axicorp Pharma B.V., The Hague, The Netherlands; Abacus Medicine A/S, Copenhagen, Denmark; EurimPharm Arzneimittel GmbH, Saaldorf-Surheim 10. Leuprorelin: Orifarm GmbH, Leverkusen; Hexal AG, Holzkirchen 11. Macrogol and Macrogol in combinations: Aliud Pharma GmbH, Laichingen; Zentiva Pharma GmbH, Berlin; 1 A Pharma GmbH, Holzkirchen; betapharm Arzneimittel GmbH, Augsburg 12. Omalizumab: Novartis Pharma GmbH, Nuremberg 13. Oxycodone and naloxone: HENNIG ARZNEIMITTEL GmbH & Co. KG, Flörsheim am Main 14. Pimecrolimus: Viatris Healthcare GmbH, Bad Homburg 15. Raltegravir: Paranova Pack A/S, Herlev, Denmark 16. Ribociclib: Paranova Pack A/S, Herlev, Denmark; Abacus Medicine A/S, Copenhagen, Denmark; Originalis B.V., Amsterdam, Netherlands 17. Rivaroxaban FTA (excluding 2,5mg): 1 0 1 Carefarm GmbH, Leverkusen; kohlpharma GmbH, Merzig 18. tacrolimus: Orifarm GmbH, Leverkusen; Heumann Pharma GmbH & Co. Generica KG, Nuremberg; EMRA-MED Arzneimittel GmbH, Trittau; axicorp Pharma B.V., The Hague, The Netherlands; Aliud Pharma GmbH, Laichingen; 1 0 1 Carefarm GmbH, Leverkusen; Abacus Medicine A/S, Copenhagen, Denmark; ACA Müller ADAG Pharma AG, Gottmadingen; Astellas Pharma GmbH, Munich; CC Pharma GmbH, Densborn; Chiesi GmbH, Hamburg; EurimPharm Arzneimittel GmbH, Saaldorf-Surheim; kohlpharma GmbH, Merzig; Originalis B.V., Amsterdam, Netherlands; PB Pharma GmbH, Meerbusch; STADAPHARM GmbH, Bad Vilbel 19. Teriparatide: EMRA-MED Arzneimittel GmbH, Trittau 20. Tocilizumab: axicorp Pharma B.V., The Hague, The Netherlands; Medicopharm AG_Nußdorf am Inn; NMG Pharma GmbH, Bonn 21. ustekinumab: Amgen GmbH, Munich; Hexal AG, Holzkirchen; Johnson&Johnson - Janssen-Cilag GmbH, Neuss; STADAPHARM GmbH, Bad Vilbel 22. Bevacizumab: Zentiva Pharma GmbH, Berlin 23. Bortezomib: Zentiva Pharma GmbH, Berlin 24. Botulinum toxin type A: 1 4 U Pharma GmbH, Densborn; Abacus Medicine A/S, Copenhagen, Denmark; Originalis B.V., Amsterdam, Netherlands 25. Estradiol: 1 A Pharma GmbH, Holzkirchen 26. Allergen extracts from grass pollen (Oralair): Abacus Medicine A/S, Copenhagen, Denmark 27. Tolvaptan: Abacus Medicine A/S, Copenhagen, Denmark 28. Doravirin: HAEMATO PHARM GmbH, Schönefeld 29. Glatiramer acetate: Originalis B.V., Amsterdam, Netherlands; 30. Dolutegravir and rilpivirine: ViiV Healthcare GmbH, Munich
Text automatically translated in your browsing language
Automatically translated
